Characterizing the evolution of Subjective Cognitive Decline in preclinical Alzheimer's disease

项目摘要 随着阿尔茨海默病(AD)的治疗策略越来越注重临床前阶段的预防， 迫切需要相应的努力来改进对认知功能早期变化的检测。主观性 认知衰退(SCD)提供了一个独特的机会来识别新出现的认知症状 可以补充临床前阶段的神经心理学评估的个人视角。 此外，SCD还直接应用于AD预防试验，试图证明治疗效果 这对研究参与者的日常生活产生了影响。我们建议招募一批新的SCD患者，他们报告说 对认知功能近期持续变化的担忧。个人将从这两个部门招聘 社区和记忆障碍诊所(n=100)，并将在3年内进行跟踪。 具体地说，我们将捕获可以在无监督情况下管理的高频SCD报告(即季度报告 通过个人电子设备(例如，计算机、智能手机、平板电脑)。通过这种方式，参与者将能够 在家里完成评估，而不是来诊所。SCD轨迹将与其他 疾病严重程度的标志，包括体内纵向AD生物标志物，淀粉样蛋白(匹兹堡化合物B- 和tau与客观认知功能下降有关。从这些信息中收集到的信息 互补的方法将提高我们识别更有可能下降的高风险参与者的能力 追踪对治疗有临床意义的反应。

Project Summary As Alzheimer's disease (AD) treatment strategies increasingly focus on prevention at the preclinical stage, a corresponding effort to improve detection of early changes in cognitive function is urgently needed. Subjective Cognitive Decline (SCD) provides a unique opportunity to identify emerging cognitive symptoms from the person's own perspective that can complement neuropsychological assessment at the preclinical stage. Furthermore, SCD has direct applications for AD prevention trials seeking to demonstrate treatment effects that impact study participants' daily lives. We propose to recruit a new cohort of SCD individuals who report a concern for recent, persistent changes in cognitive functioning. Individuals will be recruited from both the community and the memory disorders clinics (n=100) and will be followed over the course of 3 years. Specifically, we will capture high frequency SCD report (i.e., quarterly) that can be administered unsupervised via personal electronic device (e.g., computer, smart phone, tablet). In this way, participants will be able to complete assessments at-home, rather than coming to the clinic. SCD trajectories will be associated with other markers of disease severity, including in vivo AD biomarkers longitudinally, amyloid (Pittsburgh Compound B- PET) and tau (Flortaucipir-PET) and objective cognitive decline. The information gleaned from these complementary methods will improve our ability to identify high risk participants more likely to decline and to track clinically meaningful response to treatment.